Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses

Radiotherapy can induce various adverse effects including fibrosis in cancer patients. Radiation‐induced aberrant expression of profibrotic genes has been associated with dysregulated epigenetic mechanisms. Pan‐BET (bromodomain and extraterminal domain) inhibitors, such as JQ1 and I‐BET151, have bee...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2022-07, Vol.151 (2), p.275-286
Hauptverfasser: Liu, Chun‐Shan, Rioja, Inmaculada, Bakr, Ali, Veldwijk, Marlon R., Sperk, Elena, Herskind, Carsten, Weichenhan, Dieter, Prinjha, Rab K., Plass, Christoph, Schmezer, Peter, Popanda, Odilia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 286
container_issue 2
container_start_page 275
container_title International journal of cancer
container_volume 151
creator Liu, Chun‐Shan
Rioja, Inmaculada
Bakr, Ali
Veldwijk, Marlon R.
Sperk, Elena
Herskind, Carsten
Weichenhan, Dieter
Prinjha, Rab K.
Plass, Christoph
Schmezer, Peter
Popanda, Odilia
description Radiotherapy can induce various adverse effects including fibrosis in cancer patients. Radiation‐induced aberrant expression of profibrotic genes has been associated with dysregulated epigenetic mechanisms. Pan‐BET (bromodomain and extraterminal domain) inhibitors, such as JQ1 and I‐BET151, have been reported to attenuate the profibrotic response after irradiation. Despite their profound preclinical efficacy, the clinical utility of pan‐inhibitors is limited due to observed cytotoxicicities. Recently, inhibitors were developed that selectively target the first (BD1) and second (BD2) bromodomain of the BET proteins (iBET‐BD1 [GSK778] and iBET‐BD2 [GSK046]). Here, their potential to attenuate radiation‐induced fibroblast activation with low‐toxicity was investigated. Our results indicated that cell proliferation and cell cycle progression in fibroblasts from BJ cells and six donors were reduced when treated with I‐BET151 and iBET‐BD1, but not with iBET‐BD2. After irradiation, induction of DGKA and profibrotic markers, especially COL1A1 and ACTA2, was attenuated with all BET inhibitors. H3K27ac enrichment was similar at the DGKA enhancer region after I‐BET151 treatment and irradiation, but was reduced at the COL1A1 transcription start site and the ACTA2 enhancer site. iBET‐BD2 did not change H3K27ac levels in these regions. BRD4 occupancy at these regions was not altered by any of the compounds. Cell migration activity was measured as a characteristic independent of extracellular matrix production and was unchanged in fibroblasts after irradiation and BET inhibitor‐treatment. In conclusion, iBET‐BD2 efficiently suppressed radiation‐induced expression of DGKA and profibrotic markers without showing cytotoxicity. Thus BD2‐selective targeting is a promising new therapeutic avenue for further investigations to prevent or attenuate radiotherapy‐induced fibrosis. What's new? Radiation therapy for cancer can cause fibrosis by disrupting epigenetic control mechanisms that activate pro‐fibrotic genes. Inhibitors that broadly target the bromodomain and extra‐terminal (BET) domain family can combat this activity, but aren't clinically useful due to high toxicity. Here, the authors tested bromodomain‐selective inhibitors and found that iBET‐BD2, which targets the second bromodomain of BET proteins, lessens the activation of pro‐fibrotic genes with only minor cytotoxicity. This inhibitor could be a promising option for reducing fibrosis in cancer survivors.
doi_str_mv 10.1002/ijc.33989
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2635474229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2635474229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3889-49a93030dafbd7fa324e500b40a8661ab84241a08954f9ab86160ec9434d217c3</originalsourceid><addsrcrecordid>eNp10c1KHTEUB_Aglnpru_AFJODGLkZPPuYjy3q1ahFcaNdDJjmDucwkt8lMiwvBR-gz9kma67VdFLo6CefHnwN_Qg4YnDAAfupW5kQI1agdsmCg6gI4K3fJIu-gqJmo9si7lFYAjJUg35I9UXKhWCMX5OkOBzST-47U-QfXuSnERENPuxjGYMOonadn54xqb_Pkm9XZxT1dxzCh84lmNA96Qhq1dXpywf96_um8nQ3ajepdTpqcoS-PbtBpohHTOviE6T150-sh4YfXuU--fr64X14VN7eX18tPN4URTaMKqbQSIMDqvrN1rwWXWAJ0EnRTVUx3jeSSaWhUKXuVvxWrAI2SQlrOaiP2yfE2Nx_0bcY0taNLBodBewxzanklSllLzlWmR__QVZijz9dlVTWZyBKy-rhVJoaUIvbtOrpRx8eWQbvppM2dtC-dZHv4mjh3I9q_8k8JGZxuwQ834OP_k9rrL8tt5G8hB5aD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2668229450</pqid></control><display><type>article</type><title>Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses</title><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Liu, Chun‐Shan ; Rioja, Inmaculada ; Bakr, Ali ; Veldwijk, Marlon R. ; Sperk, Elena ; Herskind, Carsten ; Weichenhan, Dieter ; Prinjha, Rab K. ; Plass, Christoph ; Schmezer, Peter ; Popanda, Odilia</creator><creatorcontrib>Liu, Chun‐Shan ; Rioja, Inmaculada ; Bakr, Ali ; Veldwijk, Marlon R. ; Sperk, Elena ; Herskind, Carsten ; Weichenhan, Dieter ; Prinjha, Rab K. ; Plass, Christoph ; Schmezer, Peter ; Popanda, Odilia</creatorcontrib><description>Radiotherapy can induce various adverse effects including fibrosis in cancer patients. Radiation‐induced aberrant expression of profibrotic genes has been associated with dysregulated epigenetic mechanisms. Pan‐BET (bromodomain and extraterminal domain) inhibitors, such as JQ1 and I‐BET151, have been reported to attenuate the profibrotic response after irradiation. Despite their profound preclinical efficacy, the clinical utility of pan‐inhibitors is limited due to observed cytotoxicicities. Recently, inhibitors were developed that selectively target the first (BD1) and second (BD2) bromodomain of the BET proteins (iBET‐BD1 [GSK778] and iBET‐BD2 [GSK046]). Here, their potential to attenuate radiation‐induced fibroblast activation with low‐toxicity was investigated. Our results indicated that cell proliferation and cell cycle progression in fibroblasts from BJ cells and six donors were reduced when treated with I‐BET151 and iBET‐BD1, but not with iBET‐BD2. After irradiation, induction of DGKA and profibrotic markers, especially COL1A1 and ACTA2, was attenuated with all BET inhibitors. H3K27ac enrichment was similar at the DGKA enhancer region after I‐BET151 treatment and irradiation, but was reduced at the COL1A1 transcription start site and the ACTA2 enhancer site. iBET‐BD2 did not change H3K27ac levels in these regions. BRD4 occupancy at these regions was not altered by any of the compounds. Cell migration activity was measured as a characteristic independent of extracellular matrix production and was unchanged in fibroblasts after irradiation and BET inhibitor‐treatment. In conclusion, iBET‐BD2 efficiently suppressed radiation‐induced expression of DGKA and profibrotic markers without showing cytotoxicity. Thus BD2‐selective targeting is a promising new therapeutic avenue for further investigations to prevent or attenuate radiotherapy‐induced fibrosis. What's new? Radiation therapy for cancer can cause fibrosis by disrupting epigenetic control mechanisms that activate pro‐fibrotic genes. Inhibitors that broadly target the bromodomain and extra‐terminal (BET) domain family can combat this activity, but aren't clinically useful due to high toxicity. Here, the authors tested bromodomain‐selective inhibitors and found that iBET‐BD2, which targets the second bromodomain of BET proteins, lessens the activation of pro‐fibrotic genes with only minor cytotoxicity. This inhibitor could be a promising option for reducing fibrosis in cancer survivors.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.33989</identifier><identifier>PMID: 35239184</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>BET ; Cancer ; Cell cycle ; Cell migration ; Cell proliferation ; Collagen (type I) ; Cytotoxicity ; Epigenetics ; Extracellular matrix ; fibroblast activation ; Fibroblasts ; Fibrosis ; Medical research ; radiation ; Radiation therapy ; selective bromodomain inhibitors</subject><ispartof>International journal of cancer, 2022-07, Vol.151 (2), p.275-286</ispartof><rights>2022 The Authors. published by John Wiley &amp; Sons Ltd on behalf of UICC.</rights><rights>2022 The Authors. International Journal of Cancer published by John Wiley &amp; Sons Ltd on behalf of UICC.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3889-49a93030dafbd7fa324e500b40a8661ab84241a08954f9ab86160ec9434d217c3</citedby><cites>FETCH-LOGICAL-c3889-49a93030dafbd7fa324e500b40a8661ab84241a08954f9ab86160ec9434d217c3</cites><orcidid>0000-0001-6554-5907 ; 0000-0002-2666-3326 ; 0000-0002-6111-0591 ; 0000-0002-8771-8124 ; 0000-0002-0533-2253 ; 0000-0003-2554-3952 ; 0000-0003-0887-0484</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.33989$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.33989$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35239184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Chun‐Shan</creatorcontrib><creatorcontrib>Rioja, Inmaculada</creatorcontrib><creatorcontrib>Bakr, Ali</creatorcontrib><creatorcontrib>Veldwijk, Marlon R.</creatorcontrib><creatorcontrib>Sperk, Elena</creatorcontrib><creatorcontrib>Herskind, Carsten</creatorcontrib><creatorcontrib>Weichenhan, Dieter</creatorcontrib><creatorcontrib>Prinjha, Rab K.</creatorcontrib><creatorcontrib>Plass, Christoph</creatorcontrib><creatorcontrib>Schmezer, Peter</creatorcontrib><creatorcontrib>Popanda, Odilia</creatorcontrib><title>Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Radiotherapy can induce various adverse effects including fibrosis in cancer patients. Radiation‐induced aberrant expression of profibrotic genes has been associated with dysregulated epigenetic mechanisms. Pan‐BET (bromodomain and extraterminal domain) inhibitors, such as JQ1 and I‐BET151, have been reported to attenuate the profibrotic response after irradiation. Despite their profound preclinical efficacy, the clinical utility of pan‐inhibitors is limited due to observed cytotoxicicities. Recently, inhibitors were developed that selectively target the first (BD1) and second (BD2) bromodomain of the BET proteins (iBET‐BD1 [GSK778] and iBET‐BD2 [GSK046]). Here, their potential to attenuate radiation‐induced fibroblast activation with low‐toxicity was investigated. Our results indicated that cell proliferation and cell cycle progression in fibroblasts from BJ cells and six donors were reduced when treated with I‐BET151 and iBET‐BD1, but not with iBET‐BD2. After irradiation, induction of DGKA and profibrotic markers, especially COL1A1 and ACTA2, was attenuated with all BET inhibitors. H3K27ac enrichment was similar at the DGKA enhancer region after I‐BET151 treatment and irradiation, but was reduced at the COL1A1 transcription start site and the ACTA2 enhancer site. iBET‐BD2 did not change H3K27ac levels in these regions. BRD4 occupancy at these regions was not altered by any of the compounds. Cell migration activity was measured as a characteristic independent of extracellular matrix production and was unchanged in fibroblasts after irradiation and BET inhibitor‐treatment. In conclusion, iBET‐BD2 efficiently suppressed radiation‐induced expression of DGKA and profibrotic markers without showing cytotoxicity. Thus BD2‐selective targeting is a promising new therapeutic avenue for further investigations to prevent or attenuate radiotherapy‐induced fibrosis. What's new? Radiation therapy for cancer can cause fibrosis by disrupting epigenetic control mechanisms that activate pro‐fibrotic genes. Inhibitors that broadly target the bromodomain and extra‐terminal (BET) domain family can combat this activity, but aren't clinically useful due to high toxicity. Here, the authors tested bromodomain‐selective inhibitors and found that iBET‐BD2, which targets the second bromodomain of BET proteins, lessens the activation of pro‐fibrotic genes with only minor cytotoxicity. This inhibitor could be a promising option for reducing fibrosis in cancer survivors.</description><subject>BET</subject><subject>Cancer</subject><subject>Cell cycle</subject><subject>Cell migration</subject><subject>Cell proliferation</subject><subject>Collagen (type I)</subject><subject>Cytotoxicity</subject><subject>Epigenetics</subject><subject>Extracellular matrix</subject><subject>fibroblast activation</subject><subject>Fibroblasts</subject><subject>Fibrosis</subject><subject>Medical research</subject><subject>radiation</subject><subject>Radiation therapy</subject><subject>selective bromodomain inhibitors</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp10c1KHTEUB_Aglnpru_AFJODGLkZPPuYjy3q1ahFcaNdDJjmDucwkt8lMiwvBR-gz9kma67VdFLo6CefHnwN_Qg4YnDAAfupW5kQI1agdsmCg6gI4K3fJIu-gqJmo9si7lFYAjJUg35I9UXKhWCMX5OkOBzST-47U-QfXuSnERENPuxjGYMOonadn54xqb_Pkm9XZxT1dxzCh84lmNA96Qhq1dXpywf96_um8nQ3ajepdTpqcoS-PbtBpohHTOviE6T150-sh4YfXuU--fr64X14VN7eX18tPN4URTaMKqbQSIMDqvrN1rwWXWAJ0EnRTVUx3jeSSaWhUKXuVvxWrAI2SQlrOaiP2yfE2Nx_0bcY0taNLBodBewxzanklSllLzlWmR__QVZijz9dlVTWZyBKy-rhVJoaUIvbtOrpRx8eWQbvppM2dtC-dZHv4mjh3I9q_8k8JGZxuwQ834OP_k9rrL8tt5G8hB5aD</recordid><startdate>20220715</startdate><enddate>20220715</enddate><creator>Liu, Chun‐Shan</creator><creator>Rioja, Inmaculada</creator><creator>Bakr, Ali</creator><creator>Veldwijk, Marlon R.</creator><creator>Sperk, Elena</creator><creator>Herskind, Carsten</creator><creator>Weichenhan, Dieter</creator><creator>Prinjha, Rab K.</creator><creator>Plass, Christoph</creator><creator>Schmezer, Peter</creator><creator>Popanda, Odilia</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6554-5907</orcidid><orcidid>https://orcid.org/0000-0002-2666-3326</orcidid><orcidid>https://orcid.org/0000-0002-6111-0591</orcidid><orcidid>https://orcid.org/0000-0002-8771-8124</orcidid><orcidid>https://orcid.org/0000-0002-0533-2253</orcidid><orcidid>https://orcid.org/0000-0003-2554-3952</orcidid><orcidid>https://orcid.org/0000-0003-0887-0484</orcidid></search><sort><creationdate>20220715</creationdate><title>Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses</title><author>Liu, Chun‐Shan ; Rioja, Inmaculada ; Bakr, Ali ; Veldwijk, Marlon R. ; Sperk, Elena ; Herskind, Carsten ; Weichenhan, Dieter ; Prinjha, Rab K. ; Plass, Christoph ; Schmezer, Peter ; Popanda, Odilia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3889-49a93030dafbd7fa324e500b40a8661ab84241a08954f9ab86160ec9434d217c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>BET</topic><topic>Cancer</topic><topic>Cell cycle</topic><topic>Cell migration</topic><topic>Cell proliferation</topic><topic>Collagen (type I)</topic><topic>Cytotoxicity</topic><topic>Epigenetics</topic><topic>Extracellular matrix</topic><topic>fibroblast activation</topic><topic>Fibroblasts</topic><topic>Fibrosis</topic><topic>Medical research</topic><topic>radiation</topic><topic>Radiation therapy</topic><topic>selective bromodomain inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Chun‐Shan</creatorcontrib><creatorcontrib>Rioja, Inmaculada</creatorcontrib><creatorcontrib>Bakr, Ali</creatorcontrib><creatorcontrib>Veldwijk, Marlon R.</creatorcontrib><creatorcontrib>Sperk, Elena</creatorcontrib><creatorcontrib>Herskind, Carsten</creatorcontrib><creatorcontrib>Weichenhan, Dieter</creatorcontrib><creatorcontrib>Prinjha, Rab K.</creatorcontrib><creatorcontrib>Plass, Christoph</creatorcontrib><creatorcontrib>Schmezer, Peter</creatorcontrib><creatorcontrib>Popanda, Odilia</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Chun‐Shan</au><au>Rioja, Inmaculada</au><au>Bakr, Ali</au><au>Veldwijk, Marlon R.</au><au>Sperk, Elena</au><au>Herskind, Carsten</au><au>Weichenhan, Dieter</au><au>Prinjha, Rab K.</au><au>Plass, Christoph</au><au>Schmezer, Peter</au><au>Popanda, Odilia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2022-07-15</date><risdate>2022</risdate><volume>151</volume><issue>2</issue><spage>275</spage><epage>286</epage><pages>275-286</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Radiotherapy can induce various adverse effects including fibrosis in cancer patients. Radiation‐induced aberrant expression of profibrotic genes has been associated with dysregulated epigenetic mechanisms. Pan‐BET (bromodomain and extraterminal domain) inhibitors, such as JQ1 and I‐BET151, have been reported to attenuate the profibrotic response after irradiation. Despite their profound preclinical efficacy, the clinical utility of pan‐inhibitors is limited due to observed cytotoxicicities. Recently, inhibitors were developed that selectively target the first (BD1) and second (BD2) bromodomain of the BET proteins (iBET‐BD1 [GSK778] and iBET‐BD2 [GSK046]). Here, their potential to attenuate radiation‐induced fibroblast activation with low‐toxicity was investigated. Our results indicated that cell proliferation and cell cycle progression in fibroblasts from BJ cells and six donors were reduced when treated with I‐BET151 and iBET‐BD1, but not with iBET‐BD2. After irradiation, induction of DGKA and profibrotic markers, especially COL1A1 and ACTA2, was attenuated with all BET inhibitors. H3K27ac enrichment was similar at the DGKA enhancer region after I‐BET151 treatment and irradiation, but was reduced at the COL1A1 transcription start site and the ACTA2 enhancer site. iBET‐BD2 did not change H3K27ac levels in these regions. BRD4 occupancy at these regions was not altered by any of the compounds. Cell migration activity was measured as a characteristic independent of extracellular matrix production and was unchanged in fibroblasts after irradiation and BET inhibitor‐treatment. In conclusion, iBET‐BD2 efficiently suppressed radiation‐induced expression of DGKA and profibrotic markers without showing cytotoxicity. Thus BD2‐selective targeting is a promising new therapeutic avenue for further investigations to prevent or attenuate radiotherapy‐induced fibrosis. What's new? Radiation therapy for cancer can cause fibrosis by disrupting epigenetic control mechanisms that activate pro‐fibrotic genes. Inhibitors that broadly target the bromodomain and extra‐terminal (BET) domain family can combat this activity, but aren't clinically useful due to high toxicity. Here, the authors tested bromodomain‐selective inhibitors and found that iBET‐BD2, which targets the second bromodomain of BET proteins, lessens the activation of pro‐fibrotic genes with only minor cytotoxicity. This inhibitor could be a promising option for reducing fibrosis in cancer survivors.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>35239184</pmid><doi>10.1002/ijc.33989</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-6554-5907</orcidid><orcidid>https://orcid.org/0000-0002-2666-3326</orcidid><orcidid>https://orcid.org/0000-0002-6111-0591</orcidid><orcidid>https://orcid.org/0000-0002-8771-8124</orcidid><orcidid>https://orcid.org/0000-0002-0533-2253</orcidid><orcidid>https://orcid.org/0000-0003-2554-3952</orcidid><orcidid>https://orcid.org/0000-0003-0887-0484</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0020-7136
ispartof International journal of cancer, 2022-07, Vol.151 (2), p.275-286
issn 0020-7136
1097-0215
language eng
recordid cdi_proquest_miscellaneous_2635474229
source Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals
subjects BET
Cancer
Cell cycle
Cell migration
Cell proliferation
Collagen (type I)
Cytotoxicity
Epigenetics
Extracellular matrix
fibroblast activation
Fibroblasts
Fibrosis
Medical research
radiation
Radiation therapy
selective bromodomain inhibitors
title Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation‐induced profibrotic fibroblast responses
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A59%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selective%20inhibitors%20of%20bromodomain%20BD1%20and%20BD2%20of%20BET%20proteins%20modulate%20radiation%E2%80%90induced%20profibrotic%20fibroblast%20responses&rft.jtitle=International%20journal%20of%20cancer&rft.au=Liu,%20Chun%E2%80%90Shan&rft.date=2022-07-15&rft.volume=151&rft.issue=2&rft.spage=275&rft.epage=286&rft.pages=275-286&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.33989&rft_dat=%3Cproquest_cross%3E2635474229%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2668229450&rft_id=info:pmid/35239184&rfr_iscdi=true